Lunai Bioworks, Inc. (NASDAQ: LNAI) received a letter from The Nasdaq Stock Market LLC on June 11, 2026, confirming the company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Nasdaq confirmed the company met the terms outlined in the Nasdaq Hearings Panel's decision and extension letters dated April 20, 2026, and May 12, 2026.

Under Nasdaq Listing Rule 5815(d)(4)(B), the company will be subject to a mandatory Panel monitor for one year from the date of the letter. During this period, if Nasdaq staff determines the company is again out of compliance with the bid price rule, the company will not be permitted to submit a plan of compliance, and Nasdaq staff will not be permitted to grant additional time to regain compliance. No cure or compliance period under Nasdaq Listing Rule 5810(c)(3) would apply.

In such a scenario, Nasdaq staff would issue a delist determination letter, and the company would have the opportunity to request a new hearing before the Nasdaq Hearings Panel under Nasdaq Listing Rule 5815(d)(4)(C). A hearing request would stay any suspension or delisting action pending the conclusion of the hearing process.